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Medical fluorophore 1 (MF1), a benzoquinolizinium-
based fluorescent dye, as an inflammation
imaging agent†
Sang Bong Lee,‡a Ye Ri Han,‡a Hui-Jeon Jeon,‡a Chul-Ho Jun, bcd
Sang-Kyoon Kim,e Jungwook Chin, a Su-Jeong Lee,a Minseon Jeong,a
Jae-Eon Lee,ef Chang-Hee Lee,bcd Sung Jin Cho,*a Dong-Su Kim *a and
Yong Hyun Jeon *e
Structure-based targeting of fluorescent dyes is essential for their use as imaging agents for disease
diagnosis. Here, we describe the development of the benzoquinolizinium compound Medical fluorophore
1 (MF1) as a novel biomedical imaging agent that allows the visualization of inflammation by virtue of its
unique chemical structure. Lipopolysaccharide treatment stimulated the uptake of MF1 by bone marrow-
derived macrophages, with no adverse effects on cell proliferation. In vivo fluorescence lifetime imaging
revealed the accumulation of MF1 in carrageenan-induced acute inflammatory lesions in mice, which
peaked at 6 h. MF1-based imaging also allowed monitoring of the response to the anti-inflammatory
drugs dexamethasone and sulfasalazine. Thus, MF1 can be used to diagnose diseases characterized by
inflammation as well as treatment efficacy.
Introduction
Inflammation is an innate and adaptive immune response
induced by infectious pathogens such as bacteria, viruses, and
fungi1–3 as well as noxious stimuli and conditions such as tissue
injury4,5 and degeneration, cell death,6–8 cancer,9 ischemia,10 and
thrombosis.11,12 Inflammation provides a mechanism for removing
irritants and restoring tissue homeostasis. Immune activation
involves inflammation mediated by white blood cells,13 followed
by stimulation of T lymphocytes14 that results in the activation of
monocytes,15 mast cells,16,17 dendritic cells,18,19 and macro-
phages.20,21 An inadequate immune response can lead to chronic
disease; monitoring inflammation can provide insights into
pathophysiological states.
Near-infrared (NIR) fluorophores have many desirable char-
acteristics for medical imaging purposes including low tissue
attenuation, low autofluorescence, and ability to penetrate into
deep tissue.22,23 NIR fluorophores with covalently bound small
molecules,24,25 peptidomimetics,26,27 peptides,28,29 nano-
structures,30,31 and antibodies32,33 that can be targeted to
specific tissues have been developed.34–41 However, despite
their advantages the high molecular weight of modified fluoro-
phores and their complex routes of synthesis limit their wide-
spread application.
We recently reported the development of several novel
fluorescent dyes using a unique synthesis approach based on
benzoquinolizinium salts.42 One of these dyes, Medical fluoro-
phore 1 (MF1), is an attractive probe for in vivo imaging owing
to its facile synthesis, long wavelength and Stokes shift, and
biocompatibility.
Herein we demonstrate the utility of MF1 for visualizing
inflammatory lesions in vivo by optical imaging (Fig. 1) and for
evaluating the physiological response to anti-inflammatory drugs.
Experimental section
General
1H Nuclear magnetic resonance (NMR) and 13C NMR spectra
were recorded on an Avance II/DPX 400 (400 MHz 1H, 100 MHz
13C) spectrometer (Bruker, Billerica, MA, USA) with chemical
shifts reported relative to residual deuterated solvent peaks.
a New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation,
80 Chembok-ro Dong-gu Daegu, Republic of Korea.
E-mail: dongsukim1127@dgmif.re.kr, sjcho@dgmif.re.kr
b Department of Chemistry, Yonsei University, 50 Yonsei-ro, Seodaemun-gu,
Seoul 03722, Republic of Korea
c Center for NanoMedicine, Institute for Basic Science (IBS), Seoul, Republic of Korea
d Yonsei-IBS Institute, Yonsei University, Seoul 03722, Republic of Korea
e Laboratory Animal Center, Daegu-Gyeongbuk Medical Innovation Foundation, 80
Chembok-ro Dong-gu Daegu, Republic of Korea. E-mail: jeon9014@gmail.com
f Department of Biomaterials Science, College of Natural Resources and Life Science/
Life and Industry Convergence Research Institute, Pusan National University,
Pusan, Republic of Korea
† Electronic supplementary information (ESI) available. See DOI: 10.1039/c9tb01266d
‡ These authors contributed equally.
Received 24th June 2019,



















































View Journal  | View Issue
This journal is©The Royal Society of Chemistry 2019 J. Mater. Chem. B, 2019, 7, 7326--7331 | 7327
Infrared spectra were obtained using a Nicolet Impact 400
spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).
1H NMR spectra are reported as follows: chemical shift, multi-
plicity (s = singlet, d = doublet, t = triplet, q = quartet, m =
multiplet, dd = doublet of doublet, ddd = doublet of doublet of
doublet). 13C NMR spectra were referenced to the residual
CDCl3 (77.26 ppm) and MeOD-d4 (47.59 ppm). Mass spectra
were obtained in positive electrospray ionization (ESI) mode on an
LCMS-2020 system (Shimadzu, Tokyo, Japan). Column chromato-
graphy was performed using a CombiFlash Rf system with RediSep
Rf (Teledyne Isco, Lincoln, NE, USA). The final compounds were
purified by preparative high-performance liquid chromatography
(HPLC) on a Kinetex 5 mm biphenyl 100 Å GX-281 HPLC system
(Gilson, Middleton, WI, USA; column tube 250  21.2 mm inner
diameter), with ACN/H2O as eluent. The purity of compounds was
evaluated by analytical HPLC using a dual-wavelength ultraviolet
detector. Fluorescence data were recorded on an F-4500 spectro-
photometer (Hitachi, Tokyo, Japan). High resolution mass spectra
(HRMS) were acquired on a 1290 Infinity LC/6530 Accurate-
Mass Q-TOF system (Agilent Technologies, Santa Clara, CA,
USA) at Yonsei Center for Research Facilities, Yonsei University.
Commercially available reagent-grade chemicals were used as
received without further purification unless otherwise stated.
[Cp*RhCl2]2
43 and functionalized internal alkynes44,45 were
prepared as previously described.
Chemistry
Synthesis of 5-methyl-2,3-diphenylpyridine (4a; CAS No.
122801-45-0). 2-Methyl-N-phenethylprop-2-en-1-amine (1a; 0.2 mmol),
diphenylacetylene (2a; 0.4 mmol), Cu(OAc)2 (0.4 mmol), [Cp*RhCl2]2
(5 mol%), HBF4 (48% in water, 0.3 mmol), and methanol were
added to a 1 ml pressure vial. The solution was stirred at 130 1C
for 6 h, dried over anhydrous MgSO4, and filtered; the filtrate
was concentrated in vacuo. Pyridinium salt 5-methyl-1-phenethyl-
2,3-diphenylpyridin-1-ium tetrafluoroborate (3a) was obtained by
column chromatography (DCM : MeOH = 1 : 1) with a 84% yield
(white solid, 71.1 mg). The melting point was 154–156 1C. The
NMR data are as follows: 1H NMR (400 MHz, CDCl3) d 8.84 (s,
1H), 8.09 (s, 1H), 7.40 (t, J = 7.6 Hz, 1H), 7.32 (t, J = 7.6 Hz, 2H),
7.19–7.12 (m, 8H), 7.05–7.04 (m, 2H), 6.81–6.79 (m, 2H), 4.62
(t, J = 7.6 Hz, 2H), 3.05 (t, J = 8.0 Hz, 2H), 2.57 (s, 3H);
13C NMR (100 MHz, CDCl3) d 151.3, 146.8, 145.0, 142.6, 138.7,
135.5, 135.4, 130.8, 130.09, 130.04, 129.4, 129.2, 129.0, 128.8,
128.7, 128.6, 127.5, 60.7, 37.2, 18.4.
5-Methyl-1-phenethyl-2,3-diphenylpyridin-1-ium tetrafluoro-
borate (3a; 2 mmol), C2H5ONa (5 eq.), and methanol were added
to a 5 ml pressure vial. The solution was stirred at 130 1C for 6 h
and filtered; the filtrate was concentrated in vacuo. 5-Methyl-2,3-
diphenylpyridine (4a) was obtained by column chromatography
(Hex : EA = 5 : 1) with a 78% yield (white solid, 382.7 mg). The
NMR data are as follows: 1H NMR (400 MHz, CDCl3) d 8.54
(d, J = 1.6 Hz, 1H), 7.55 (d, J = 1.2 Hz, 1H), 7.37–7.34 (m, 2H),
7.28–7.25 (m, 3H), 7.24–7.23 (m, 3H), 7.20–7.17 (m, 2H), 2.43
(s, 3H); 13C NMR (100 MHz, CDCl3) d 154.3, 148.7, 140.0, 139.8,
138.9, 135.3, 131.4, 129.7, 129.4, 128.1, 127.7, 127.4, 127.0, 17.8.
Synthesis of 3-methyl-1-phenyl-6,7-dipropylpyrido[2,1-a]-
isoquinolin-5-ium tetrafluoroborate (6a; MF1). 5-Methyl-2,3-
diphenylpyridine (4a; 0.2 mmol), 4,40-(ethyne-1,2-diyl)bis(N,N-
dimethylaniline) (5a; 0.4 mmol), Cu(OAc)2 (0.4 mmol), [Cp*RhCl2]2
(5 mol%), NaBF4 (0.3 mmol), and methanol were added to a 1 ml
pressure vial. The solution was stirred at 130 1C for 6 h, dried over
anhydrous MgSO4, and filtered; the filtrate was concentrated in
vacuo. 6,7-Bis(4-(dimethylamino)phenyl)-3-methyl-1-phenylpyrido-
[2,1-a]isoquinolin-5-ium tetrafluoroborate was obtained by pre-
parative HPLC (ACN:H2O) with a 99% yield (6a, MF1; brown
solid, 117.9 mg). The NMR data are as follows: 1H NMR
(400 MHz, MeOD-d4) d 8.79 (s,1H), 8.39 (s, 1H), 8.02
(d, J = 8.6 Hz, 1H), 7.77 (t, J = 7.7 Hz, 1H), 7.66–7.58 (m, 6H),
7.40 (t, J = 7.9 Hz, 1H), 7.34 (d, J = 8.5 Hz, 2H), 7.25 (q, J = 8.6 Hz,
4H), 6.87 (d, J = 8.7 Hz, 2H), 3.15 (s, 6H), 3.04 (s, 6H), 2.55
(s, 3H); 13C NMR (100 MHz, MeOD-d4) d 150.8, 146.4, 144.1,
141.9, 140.1, 139.8, 139.4, 136.2, 134.5, 133.8, 133.6, 132.5,
131.7, 131.5, 129.8, 129.4, 129.2, 128.5, 127.8, 126.7, 124.7,
118.5, 115.9, 112.5, 42.2, 39.0, 17.0; IR (neat): 2919, 2803,
1658, 1609, 1431, 1059 (vB–F), 1029, 817, 730 cm
1; HRMS
(ESI) calculated for C36H34N3
+ 508.2747, found 508.2744.
Animals
Specific pathogen-free immunocompetent 6-week old C57BL/6
mice were obtained from Japan SLC (Shizuoka, Japan). All
experimental procedures involving animals were conducted in
strict accordance with the international guidelines for animal
research. The study protocol was approved by the Committee
on the Ethics of Animal Experiments of the Laboratory Animal
Center of Daegu-Gyeongbuk Medical Innovation Foundation
(approval no. DGMIF-18070202-00).
Cells
BJ normal human fibroblasts were grown in custom Dulbecco’s
modified Eagle’s medium (Hyclone, Logan, UT, USA) supplemented
with 10% fetal bovine serum (FBS; Hyclone) and 1% penicillin–
streptomycin (Gibco, Grand Island, NY, USA). Mouse bone marrow-
derived macrophages (BMDMs) were obtained from the tibia
and femur of C57BL/6 mice. Briefly, bone marrow cells were
cultured in a-Minimal Essential Medium containing 10% FBS
and 30% L929 cell-conditioned medium for 7 days. The medium
was changed every 2–3 days. BMDMs were then seeded for
subsequent experiments.
Fig. 1 In vivo FLI of acute inflammation with MF1. The dye was intrave-
nously injected into mice with carrageenan (CG)-induced inflammation,
followed by in vivo fluorescence imaging. Red dotted squares show region
of acute inflammation.














































7328 | J. Mater. Chem. B, 2019, 7, 7326--7331 This journal is©The Royal Society of Chemistry 2019
Cell proliferation assay
Cell proliferation was evaluated using Cell Counting Kit 8 (CCK-8;
Dojindo Laboratories, Tokyo, Japan). BJ cells and BMDMs were
seeded at 1  104 cells per well in 96-well plates, and 10 ml of
CCK-8 solution were added to each well after 24 h of incubation
with MF1 at a concentration of 10–25 mM, followed by incubation
at 37 1C for 1 h. Absorbance at 450 nm was measured on a
microplate reader (BMG Labtech, Offenburg, Germany).
Cytokine analysis
The culture supernatant of unlabeled or MF1-labeled BMDMs
was collected and analyzed for IL-1b, TNF-a, and IL-6 levels
using commercially available cytokine enzyme-linked immuno-
sorbent assay kits (R&D Systems, Minneapolis, MN, USA).
Immunofluorescence confocal microscopy
BMDMs were treated MF1 and lipopolysaccharide (100 ng mL1)
for 24 h and then seeded on coverslips. The cells were washed
three times with phosphate-buffered saline (PBS) and fixed over-
night at 4 1C with 1% paraformaldehyde (Sigma-Aldrich, St Louis,
MO, USA). The cells were rinsed with PBS and permeabilized with
0.1% Triton X-100 in PBS for 10 min at room temperature, then
blocked for 1 h with 10% normal goat serum in PBS. Nuclei were
stained with 40,6-diamidino-2-phenylindole (Vector Laboratories,
Burlingame, CA, USA). The samples were mounted and visualized
with a confocal laser scanning microscope (LSM 800; Carl Zeiss,
Oberkochen, Germany). Fluorescence intensity was quantified using
ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Animal studies
Study 1. The scheme for imaging acute inflammation in vivo
is shown in Fig. S7 (ESI†). Briefly, PBS and 1% carrageenan (CG)
solution were administered to separate foot pads of each
immunocompetent mouse. At 10 min after injection, MF1
(5 mg kg1) was intravenously administered followed by imaging
using an IVIS Spectrum system (PerkinElmer, Waltham, MA,
USA) at indicated times.
Study 2. The scheme for drug treatment is shown in Fig. S9
(ESI†). Mice were divided into vehicle, dexamethasone (DEX),
and sulfasalazine (SSZ) groups (n = 6 each). Inflammation was
induced as described above, and a single dose of 10 mg kg1
DEX, SSZ, or vehicle was administered to the mice immediately
afterward. Imaging was performed to visualize MF1 uptake in
footpads at indicate times. After image acquisition, the organs
were removed for ex vivo imaging.
Phenotype marker analysis
PBS and 1% CG were subcutaneously injected into the left and
right paws, respectively, of each mouse. At 10 min after injection,
MF1 was intravenously administered, and this was followed by a
FACS analysis at 6 h. The PBS- and CG-injected paws of mice
that were administered MF1 were stained with F4/80 antibody
(BD Bio science) at 4 1C for 30 min. The washed macrophage
cells were analyzed using flow cytometry. The data were analyzed
using FlowJo analysis software (FlowJo, Ashland, OR, USA).
Measurement of 1% CG-induced paw edema
PBS and 1% CG were subcutaneously injected into the left and
right paws, respectively, of each mouse. Immediately afterward,
the mice were injected with a single dose of 10 mg kg1 DEX,
SSZ, or vehicle. Paw edema was measured before (0 h, baseline)
and 3, 6, and 24 h after induction of inflammation. The change
in dorsoventral thickness of the middle portions of the injected
paws was measured using calipers as previously described.46
In vivo fluorescence imaging
In vivo fluorescence images were acquired using an IVIS Lumina
III imaging system (PerkinElmer). The scan times ranged from 1 s
to 5 min depending on the intensity of the emitted fluorescence
signal. The image was thresholded to maximize visualization of
the region of interest and minimize background fluorescence.
Grayscale and fluorescence color images were superimposed
using LIVINGIMAGE v.2.12 (PerkinElmer) and IGOR Image
Analysis FX (Wave Metrics, Lake Oswego, OR, USA) software.
Signal intensity is expressed in units of photons per cm2
per second per steradian (P cm2 s2 sr1).
Statistical analysis
Data are expressed as mean  standard deviation of at least
three independent experiments. The statistical significance of
mean differences was evaluated with the unpaired Student’s t
test using Prism v.5 software (GraphPad, La Jolla, CA, USA).
P values o 0.05 were considered statistically significant.
Results and discussion
Synthesis and characterization of MF1
We synthesized an NIR fluorophore that can be prepared via a
simple organometallic reaction catalyzed by rhodium(III) (Fig. 2a).
Briefly, the reaction of 2-methyl-N-phenethylprop-2-en-1-amine
(1a) with diphenyl acetylene (2a) and aqueous HBF4 in the
presence of (Cp*RhCl2)2 and Cu(OAc)2 forms pyridinium salt
(3a) that reacts with NaOEt in MeOH to produce 4a, with a yield
of 78%. Rh(III) catalyzes the N-annulation of 4a with 4,40-(ethyne-
1,2-diyl)bis(N,N-dimethylaniline) providing benzoquinolizinium
salt (6a, MF1), which was confirmed by 1H and 13C nuclear
magnetic resonance, liquid chromatography-mass spectrometry,
and high-performance liquid chromatography (Fig. S1–S3, ESI†).
The synthesized MF1 had excitation/emission wavelengths of
470/688 nm and a long Stokes shift at 218 nm (Fig. 2b). In
addition, the full optical characterization data of MF1 are shown
in ESI† (Table S1). In vitro fluorescence lifetime imaging (FLI)
revealed a dose-dependent increase in the fluorescence signal in
the MF1-containing tube (Fig. 2c), implying that MF1 has optical
properties that are suitable for in vivo imaging.
Cell imaging and biological functional assay
For successful in vivo application, an imaging agent should not
induce toxicity. We therefore examined the effects of MF1 on
the viability of normal fibroblasts (BJ) and bone marrow-
derived macrophages (BMDMs) and on cytokine secretion.
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As shown in Fig. S4 (ESI†), there were no differences in viability
between untreated and treated cells at various doses of MF1.
Moreover, the levels of the proinflammatory cytokines tumor
necrosis factor a, interleukin 6 (IL-6), and IL-1b did not differ
between unlabeled and labeled BMDMs, indicating that MF1
has excellent biocompatibility (Fig. S5, ESI†).
We next evaluated the potential of MF1 as an inflammation-
specific imaging agent in BMDMs, which are important effectors
in inflammatory lesions. Intact and lipopolysaccharide (LPS)-
induced BMDMs were incubated with MF1, and then assessed
by confocal fluorescence microscopy analysis. Intact BMDMs
showed MF1 accumulation in the cytoplasm but not in the
nucleus or plasma membrane (Fig. 3a). Cellular uptake of MF1
was four-fold higher in LPS-induced BMDMs as compared to that
in intact BMDMs (Fig. 3b). However, there was no uptake in
normal fibroblasts, such as 3TC-L1 and L929 cells (Fig. S6a and b,
ESI†). These data indicate that MF1 is selectively taken up by
activated but not intact macrophages.
Visualization of MF1 uptake in acute inflammation sites by
in vivo fluorescence imaging
We next performed in vivo fluorescence imaging to assess the
potential for MF1 for detecting inflammatory lesions (Fig. S7,
ESI†) using a mouse model of carrageenan (CG)-induced acute
inflammation.47 At 3 h after induction of inflammation,
MF1 accumulation was observed in the CG-injected paw, with
a peak signal intensity at 6 h (Fig. 4a, b and d). There were no
significant differences in FLI signal intensity between phosphate-
buffered saline- and CG-injected paws at 24 h. Consistent with the
in vivo FLI results, measurement of dorsoventral thickness of
the middle portions of hind paws revealed maximal swelling in
CG-injected paws at 6 h, with severe paw edema persisting up to
24 h (Fig. 4c and e). Because the highest uptake was observed in
paw edema at 6 h post-injection of MF1, the PBS-injected and
CG-injected paws were excised for FACS analysis to examine the
percentage of F4/80+ (active macrophage specific marker) and
Fig. 2 Route of synthesis and optical properties of MF1. (a) Scheme of
MF1 synthesis. (b) Fluorescence spectrum of MF1. (c) In vitro FLI signals in
tubes containing various concentrations of MF1 (upper: in vitro FLI image;
bottom: quantification of FLI signal).
Fig. 3 Uptake of MF1 by BMDMs. (a) Confocal laser scanning microscopy
(CLSM) images of BMDMs incubated with MF1 at 37 1C for 1 h. Blue, 40,6-
diamidino-2-phenylindole (DAPI); red, MF1. (b) Quantification of CLSM
signals from panel a. Experiments were performed at least in triplicate and
values represent mean  SD. ***P o 0.001.
Fig. 4 In vivo visualization of an acute inflammatory lesion using MF1.
(a) In vivo imaging of selective MF1 uptake in inflamed lesions over time.
Yellow and white dotted circles indicate phosphate-buffered saline (PBS)-
and CG-injected paws, respectively. (b) Region of interest analysis for
quantification of fluorescence signal in paws. (c) Measurement of paw
thickness. (d) MF1 uptake ratio of CG- to PBS-injected paws. (e) Paw
thickness ratio of CG- to PBS-injected footpads. *P o 0.05, ***P o 0.001.
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MF1+ cells. As shown in Fig. S8 (ESI†), the F4/80+ and MF1+
cells were 7.98-fold higher in the CG-injected paw than in the
PBS-injected paw. These results indicate that MF1 can be used for
in vivo monitoring of acute inflammation.
Assessment of the effects of anti-inflammatory agents on MF1
uptake in inflammatory lesions using established
inflammation-tracking strategies
We investigated whether imaging inflammation with MF1 can
provide a means of evaluating physiological response to anti-
inflammatory drugs (Fig. S9, ESI†). We tested this in mice using
the anti-inflammatory drugs dexamethasone (DEX; a steroidal
drug) and sulfasalazine (SSZ; an antagonist of adenosine A2A
cell-surface receptors).
To assess the therapeutic efficacy of DEX and SSZ in CG-induced
acute inflammation, immunocompetent mice were injected with
the drugs immediately after inducing acute inflammation with CG,
followed by intravenous injection of MF1. As shown in Fig. 5, in vivo
FLI revealed significant inhibition of MF1 uptake in the CG-injected
paw of DEX- and SSZ-treated mice 6 h after induction of
inflammation (Fig. 5a–c). In contrast, MF1 accumulation was
observed in the CG-injected paw of vehicle-treated mice. A
measurement of paw thickness showed significant inhibition
of paw edema in DEX- or SSZ-treated but not vehicle-treated
mice at 6 h post-CG injection (Fig. S10, ESI†).
In ex vivo imaging experiments, significant MF1 uptake was
evident in the CG-injected paw of vehicle-treated but not DEX- and
SSZ-treated mice (Fig. 6). MF1 was also detected in liver, lung,
intestine, stomach, spleen, and brain. Thus, MF1-based inflam-
mation imaging is useful for evaluating the physiological
response to anti-inflammatory drugs in living organisms.
Conclusions
In conclusion, we demonstrated the specific uptake of the
benzoquinolizinium-based MF1 bioimaging agent in LPS-induced
BMDMs with no adverse effects of cell proliferation. Importantly,
CG-induced inflammatory lesions in immunocompetent mice and
the anti-inflammatory effects of SSZ and DEX were successfully
visualized by MF1-based imaging, highlighting the utility of MF1 for
medical diagnostics. Studies are currently underway to explore other
potential applications for this MF1-based imaging platform in
cancer, rheumatism, and vascular disease.
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